- Global Pharma News & Resources

Hemophilia Treatment Market Report 2022-2030: Growth Influencers Include Preference for Prophylactic Treatment, Rise in Diagnosis Rate, Significant Rise in Usage of Recombinant Coagulation Factor -

DUBLIN--(BUSINESS WIRE)--The "Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to's offering.

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The product types studied for analyzing the overall global hemophilia treatment market are majorly segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents and desmopressin. The global hemophilia treatment market is segmented by hemophilia type into Hemophilia A, Hemophilia B and others.

With increase in healthcare expenditure, preference for prophylactic treatment, rise in diagnosis rate, significant rise in usage of recombinant coagulation factor are major contributors in growth of haemophilia market. In near future, recombinant coagulation factor concentrates would dominate the global haemophilia market.

Recombinant coagulation factor are preferred by most of the physician thus anticipated to drive the haemophilia market in the given forecast period, due to low risk of blood borne infection. Plasma derived coagulation factor is anticipated to have slow CAGR during the forecast period due to high risk of blood associated infections and less availability of plasma derived from blood (lack of blood donors).

Hemophilia is the most common blood disorder and is classified into two man types Hemophilia A and Hemophilia B. Hemophilia A, also called as classic hemophilia is the most common type, occurring due to deficiency of factor VIII levels. Hemophilia A is four times more prevalent than hemophilia B and thus dominates the global hemophilia treatment market.

Rising prevalence of Hemophilia A and increasing on-demand Hemophilia A prophylactic would boost the global hemophilia market. Hemophilia B, also well known as Christmas disease, occurs due to factor IX deficiency. Hemophilia C occurs due to deficiency of factor XI. Acquired hemophilia is result of medication, illness or pregnancy. It is rarely observed and resolved with proper treatment.

In 2021, North America dominated the global hemophilia treatment market followed by Europe. The prevalence of hemophilia is around 134 cases per one million U.S. males. Rising prevalence of hemophilia, increasing healthcare expenditure, awareness about bleeding disorder, extensive research and development in diagnostic technology and treatment, and favorable reimbursement policies, are some of the major factors that fuel the growth of hemophilia treatment market in North America.

Asia Pacific is anticipated to be the fastest growing market in the forecast period 2017-2025. Increase in incidence of hemophilia, rising awareness about disease, high disposable income, and improving healthcare infrastructure are important factors contributing to the growth of hemophilia market in Asia Pacific.

In emerging economies such as China, India there is increasing funding by the government and research institute for technological advancement in diagnostics and treatment of hemophilia and increase in use of recombinant products thus exhibiting lucrative opportunity for Asia Pacific market.

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Hemophilia Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Hemophilia Treatment market?
  • Which is the largest regional market for Hemophilia Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Hemophilia Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Hemophilia Treatment market worldwide?

Company Profiles

  • Baxter International Inc.
  • Baxalta
  • Bayer AG
  • Biogen Idec Inc.
  • Chugai Pharmaceutical Co.
  • CSL Behring
  • Genentech Inc.
  • Hospira Inc.
  • Ferring B.V.
  • Kedrion
  • Octapharma AG
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
  • Shire Plc.

Key Topics Covered:

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. Key Offerings

1.2. Market Segmentation

1.3. Research Methodology

1.3.1. Phase I - Secondary Research

1.3.2. Phase II - Primary Research

1.3.3. Phase III - Expert Panel Review

1.3.4. Assumptions

1.3.5. Approach Adopted

2. Executive Summary

2.1. Market Snapshot: Global Hemophilia Treatment Market

2.2. Global Hemophilia Treatment Market, By Product, 2021 (US$ Million)

2.3. Global Hemophilia Treatment Market, By Hemophilia Type, 2021 (US$ Million)

2.4. Global Hemophilia Treatment Market, By Geography, 2021 (US$ Million)

2.5. Impact of Covid 19

2.6. Attractive Investment Proposition by Geography, 2021

2.7. Competitive Analysis

2.7.1. Market Positioning of Key Hemophilia Treatment Market Vendors

2.7.2. Strategies Adopted by Hemophilia Treatment Market Vendors

2.7.3. Key Industry Strategies

3. Hemophilia Treatment Market: Business Outlook & Market Dynamics

3.1. Introduction

3.2. Global Hemophilia Treatment Market Value, 2020 - 2030, (US$ Million)

3.3. Market Dynamics

3.3.1. Market Drivers

3.3.2. Market Restraints

3.3.3. Key Challenges

3.3.4. Key Opportunities

3.4. Impact Analysis of Drivers and Restraints

3.5. See-Saw Analysis

3.6. Porter's Five Force Model

3.6.1. Supplier Power

3.6.2. Buyer Power

3.6.3. Threat Of Substitutes

3.6.4. Threat Of New Entrants

3.6.5. Competitive Rivalry

3.7. PESTEL Analysis

3.7.1. Political Landscape

3.7.2. Economic Landscape

3.7.3. Technology Landscape

3.7.4. Legal Landscape

3.7.5. Social Landscape

4. Hemophilia Treatment Market: By Product, 2020-2030, USD (Million)

4.1. Market Overview

4.2. Growth & Revenue Analysis: 2021 Versus 2030

4.3. Market Segmentation

4.3.1. Plasma Derived Coagulation Factor Concentrates Factor VIII Factor Combination

4.3.2. Recombinant Coagulation Factor Concentrates Factor VIII Factor Combination

4.3.3. Antifibrinolytic Agents

4.3.4. Desmopressin

5. Hemophilia Treatment Market: By Hemophilia Type, 2020-2030, USD (Million)

5.1. Market Overview

5.2. Growth & Revenue Analysis: 2021 Versus 2030

5.3. Market Segmentation

5.3.1. Hemophilia A

5.3.2. Hemophilia B

5.3.3. Others

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 12-Dec-2022